On 29th July 2016 Takeda Pharmaceutical Company Limited announced plans to accelerate the research & development (R&D) organization transformation by refocusing on three key therapeutic areas – Oncology, Gastroenterology (GI) and Central Nervous System (CNS), plus Vaccines, and concentrating R&D activities in Japan and the U.S.
Following a consultation process the decision to close Takeda Cambridge Ltd was made on 10th October 2016.
Any enquires or questions relating to Takeda Cambridge Ltd should be directed to:
Takeda Cambridge Ltd
418 Science Park
Telephone: +44 203 116 8000